论文部分内容阅读
目的:探讨中医药联合化疗治疗胃癌术后的有效性及安全性。方法:将我院消化内科2009年3月—2012年3月收治122例Ⅱ～Ⅲ期胃癌术后患者随机分为单纯化疗组和联合治疗组,每组各61例。观察患者化疗期间的不良反应及术后6、12及24个月的生存率,同时比较两组治疗前后免疫功能指标的变化。结果:两组患者术后6、12个月生存率无显著性差异(P>0.05),而术后24个月,联合治疗组的生存率显著高于单纯化疗组,差异有统计学意义(P<0.05)。治疗后比较,联合治疗组CD3+、CD4+及CD4+/CD8+均明显高于单纯化疗组,差异有统计学意义(P<0.05)。单纯化疗组和联合治疗组不良反应发生率分别为41.0%、19.7%,差异有统计学意义(P<0.05)。结论:中医药联合化疗治疗胃癌术后患者,可减轻化疗不良反应,提高机体免疫力,改善术后生存率。
Objective: To investigate the efficacy and safety of traditional Chinese medicine combined with chemotherapy in the treatment of gastric cancer. Methods: 122 cases of stage Ⅱ ~ Ⅲ gastric cancer patients who were admitted to our hospital from March 2009 to March 2012 were randomly divided into chemotherapy group (n = 61) and combination therapy group (n = 61). The adverse reactions during chemotherapy and the survival rates at 6, 12 and 24 months after operation were observed. The changes of immune function before and after treatment were also compared. Results: There was no significant difference in the survival rate between the two groups at 6 and 12 months (P> 0.05), but at 24 months after operation, the survival rate in the combined treatment group was significantly higher than that in the chemotherapy alone group (P <0.05) P <0.05). After treatment, the levels of CD3 +, CD4 + and CD4 + / CD8 + in the combined treatment group were significantly higher than those in the chemotherapy alone group (P <0.05). The incidence of adverse reactions in the chemotherapy group and the combination therapy group were 41.0% and 19.7%, respectively, with significant difference (P <0.05). Conclusion: Chinese medicine combined with chemotherapy for postoperative patients with gastric cancer can reduce chemotherapy adverse reactions, improve immunity and improve postoperative survival rate.